All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
In chimeric antigen receptor (CAR) therapy, immune cells are taken from the patient, genetically modified to express the CAR construct, and then infused back into the patient. To date, most CAR therapies use engineered T cells, which express the targeted cancer cell antigen. New approaches explore the use of NK cells, allogeneic cell sources, and novel CAR constructs to optimize manufacturing and improve clinical outcomes.